News & Press Releases

Filter
404 found

Three MMV-supported antimalarials listed as essential medicines

16 Jun 2017
Access & product management

MMV and GSK announce positive headline phase III results showing single-dose tafenoquine reduces risk of relapse in patients with Plasmodium vivax malaria

12 Jun 2017
R&D

Dr Tedros Adhanom Ghebreyesus elected as the new Director-General of WHO

24 May 2017
General

MMV and partners launch “call to action” to G20 health ministers

22 May 2017
General

MMV launches new Severe Malaria Observatory

18 May 2017
General

MMV and Aga Khan Foundation Canada come together to tackle malaria in Mali

01 May 2017
Access & product management

New publication highlights efficacy of MMV048 against resistant strains of malaria

27 Apr 2017
R&D

New antimalarial compound treats and protects in a single dose

29 Mar 2017
R&D

MMV 4th in top 10 rare infectious disease drug developers

28 Mar 2017
General

Awa Marie Coll-Seck receives Best Minister Award

27 Feb 2017
General

MMV shines a light on malaria in Times Square

22 Feb 2017
General

RBM appoints new CEO

27 Jan 2017
General

MMV delivers statement at 140th session of the WHO Executive Board

27 Jan 2017
General

MMV welcomes the launch of the End Malaria Council

25 Jan 2017
General

MMV brings new partner Janssen Pharmaceuticals on board

19 Jan 2017
Partner

MMV end-of-year review 2016

22 Dec 2016
General

Swiss Malaria Group invites you to enter photo and video competition

17 Dec 2016
General

Cipla’s artesunate suppository first to be quality-assured by Global Fund

16 Dec 2016
Access & product management

World Malaria Report 2016 reveals improved malaria control for vulnerable but substantial gaps remain

13 Dec 2016
General

MMV partner GSK ranked first in the Access to Medicine Index – again

17 Nov 2016
Access & product management

MMV partner Prof. David Fidock wins the 2016 Advance Global Australian of the Year Award in Life Sciences

21 Oct 2016
R&D

MMV and Zydus join forces to develop new antimalarial

27 Sep 2016
R&D

First open source malaria publication describes new way to do drug discovery

14 Sep 2016
R&D, Open source

PLOS Pathogens publishes the Malaria Box findings

28 Jul 2016
R&D, Open source

UCT-H3D, MMV and international partners identify second potent antimalarial candidate

27 Jul 2016
R&D

MMV awards seven endemic-region scientists Challenge Grants to ‘exploit the Pathogen Box’

25 Jul 2016
R&D

MMV and Novartis expand partnership

15 Jun 2016
Partner

Malaria community mourns the tragic loss of Dr Sylvia Meek

23 May 2016
General

Netherlands-based consortium teams up with MMV in world-leading malaria translational research programme

25 Apr 2016
R&D

MMV joins Swiss Malaria Group in Bern to commemorate World Malaria Day

25 Apr 2016
General

Pyramax® granules (pyronaridine-artesunate) for children added to WHO list of prequalified medicines

20 Apr 2016
Access & product management

Endemic-Region Challenge Grants of USD 50,000 each available to exploit the Pathogen Box

31 Mar 2016
Open source, R&D
children

MMV announces collaborative agreement with S Kant HEALTHCARE Ltd

10 Mar 2016

MMV welcomes WHO approval of 3-year shelf-life for antimalarial ASMQ

08 Mar 2016
Access & product management

Mr Yong Taek Chang, Chairman of Shin Poong Pharmaceutical passes away

07 Mar 2016

MMV delivers statement at WHO Executive Board meeting

29 Jan 2016
General

MMV welcomes George Osborne and Bill Gates’ £3 billion pledge for malaria

27 Jan 2016

MMV launches the Pathogen Box

14 Dec 2015
R&D

Delivery of Coartem® Dispersible reaches a landmark of 300 million treatments

09 Dec 2015
Access & product management

WHO reports a ‘dramatic decline’ in malaria burden since 2000

09 Dec 2015
General

Ray Chambers entrusts Chairmanship of MMV to Per Wold-Olsen

04 Dec 2015
General

Pyramax® Granules becomes first paediatric antimalarial to receive EMA Article 58 positive scientific opinion

20 Nov 2015
Access & product management, Partner, R&D
European regulators grant Pyramax® a revised label

European regulators grant Pyramax® a revised label

20 Nov 2015
Access & product management, Partner, R&D
Social media award winners

2015 Social media malaria heroes announced

17 Nov 2015
General

MMV provides QIMR Berghofer AU$10 M for malaria drug development

08 Nov 2015
Donors, R&D

GHIT invests $10.7 million in malaria, TB, leishmaniasis and dengue research

05 Nov 2015
Donors, Partner, R&D

Eurartesim® (dihydroartemisinin-piperaquine) receives WHO prequalification

26 Oct 2015
Access & product management
Prof. Djimde and students at WANECAM Molecular Biology Workshop MRC Gambia

New study details safety and efficacy of re-treatment with Pyramax®

23 Oct 2015
R&D

Comic books, science fiction and colour inspire two of ‘175 Faces of Chemistry’

09 Oct 2015

Nobel in Medicine awarded to parasitic disease drug pioneers

05 Oct 2015
General

Leader in the fight against malaria passes away

21 Sep 2015
General

WHO awards over $1 million to MMV’s ‘Exploiting the Pathogen Box’ project

19 Aug 2015
Open source, R&D

Call to nominate forward-thinking malaria heroes

13 Aug 2015
General

MMV welcomes launch of WHO P. vivax technical brief

29 Jul 2015
General

OZ439 recognized as a high-impact innovation to transform global health

16 Jul 2015
R&D

Pre-clinical assessment of exciting new malaria drug candidate published

16 Jul 2015
R&D

MMV wins Tim Berners-Lee’s Open Data Innovation Award

10 Jul 2015
R&D, Open source

New compound has the potential to treat malaria patients in a single dose

17 Jun 2015
Partner, R&D

GHIT, Takeda and MMV progress first-in-class antimalarial DSM265 to patient trials in Peruvian Amazon

05 Jun 2015
Partner, R&D
Dr David Reddy, CEO, MMV and Dr Bernard Pécoul, CEO, DNDi

DNDi passes the ball to MMV

22 May 2015
Access & product management

Pages